Navigation Links
Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Date:11/27/2007

Lead Selections Trigger Milestone Payments Totaling $1 Million to

Pharmacopeia

PRINCETON, N.J., Nov. 27 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it has identified two new lead compounds for advancement in its alliance with GlaxoSmithKline (NYSE: GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disease. The other newly identified lead compound is the second from a program in inflammatory pain. As a result of the identification of these new lead compounds, Pharmacopeia will receive milestone payments totaling $1 million from GSK.

Under the terms of the companies' collaboration, Pharmacopeia has received $10 million from GSK in connection with early discovery activities and is entitled to an additional $5 million payment upon the completion of additional early discovery activities. Pharmacopeia is also entitled to success-based milestone payments totaling up to $83 million per program and potentially double-digit royalties on the sales of any product commercialized by GSK under the multi-program alliance. Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia may independently pursue them, subject to its obligations to GSK under the agreement.

"With the identification of these two compounds, our collaboration has now identified a total of three new leads this year," said Hugh Cowley, Senior Vice President of GSK and head of the CEED
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmacopeia Announces Senior Additions to Management Team
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. GlaxoSmithKline Responds to JAMA Articles
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
6. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
7. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
8. GlaxoSmithKline Aids California Fire Relief Efforts
9. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Register to ... one of the most active years on record for life ... in life sciences represented 22 percent of all venture dollars ... exits and achieved high valuations. , However, 2014 is ... a recent report by Silicon Valley Bank, while life sciences ...
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
(Date:7/31/2014)... The 2013 PolyU TSI hit ... from 75.07 in 2012. The index measures inbound ... integrates them into an overall index. The 2013 ... satisfied with Hong Kong over time. , The ... service performance in Hong Kong are attractions (79.27) ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... At the end of a 10-year, coast-to-coast study of women ... Jr., M.D., and three fellow researchers are making the case ... in their tracks. In the August 2009 issue of ... professor of surgery at Dartmouth Medical School (DMS), and his ...
... Texas Health Science Center at Houston has been awarded a ... a center to conduct innovative cancer research. The center will ... funds totaling $11.6 million over a 5-year period. The new ... The CTO is one of the first 12 Physical Sciences-Oncology ...
... interventional radiologist one Friday night three years ago when he ... Hospital & Clinics. He was asked to attend to a ... to the emergency room with massive blood clots in her ... what happened," said Kuo, assistant professor of radiology at the ...
... all products tested contained lead and some had known skin ... little goblins or vampires are set to paint their faces ... want to think twice, according to a new report released ... by the Campaign for Safe Cosmetics, is titled: Pretty ...
... Oct. 27 Dr. Lawrence Brown of Philadelphia, Pennsylvania has ... national nonprofit organization advocating for children and adolescents with neurologic ... three years. Dr. Brown works for Children,s Hospital of ... 2006. , Dr. Brown,s first order of business will be ...
... Life Extension® the global authority on nutrition, ... of scientific information on anti-aging supplements and therapies, ... with 50 mg of Setria® Glutathione from Kyowa ... available from Life Extension® in 100 count bottles ...
Cached Medicine News:Health News:UT leads collaborative initiative for innovative cancer research 2Health News:UT leads collaborative initiative for innovative cancer research 3Health News:UT leads collaborative initiative for innovative cancer research 4Health News:Stanford study recommends change in treating pulmonary embolisms 2Health News:Stanford study recommends change in treating pulmonary embolisms 3Health News:Stanford study recommends change in treating pulmonary embolisms 4Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Dr. Lawrence Brown Named President of the Child Neurology Foundation 2Health News:Life Extension(R) Introduces Glutathione, Cysteine & C Formulation With Setria(R) From Kyowa Hakko USA 2
(Date:7/31/2014)... , July 31, 2014 Catylix, Inc. ... Scientific ( Milpitas, California ) announced ... develop and commercialize new fluorination products and related ... has benefited from the use of substituents that ... lipophilicity with polarity to improve binding and bioavailability. ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Cyberonics, Inc. (Nasdaq: CYBX ) today announced that the ... 23, 2009 of its fiscal year ending April 30, 2010 on ... will conduct a conference call to discuss those results on Thursday, ... Year 2010 Second Quarter Results Conference Call Instructions , ...
... November 6 , - ... for the,Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections , ... focused on the discovery and,development of novel antibiotics designed ... today that its most advanced oral,antibacterial NXL103 (flopristin/linopristin), has ...
Cached Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
... Tox A/B II is a second-generation rapid ELISA ... and B in fecal specimens. The test utilizes ... detecting not only the more common toxin A+ ... It's easy to perform, produces no indeterminates and ...
Medicine Products: